Immunome, Inc. (IMNM)

NASDAQ: IMNM · IEX Real-Time Price · USD
24.68
-0.84 (-3.29%)
At close: Mar 28, 2024, 4:00 PM
25.60
+0.92 (3.73%)
After-hours: Mar 28, 2024, 5:22 PM EDT
-3.29%
Market Cap 1.49B
Revenue (ttm) 10.19M
Net Income (ttm) -21.96M
Shares Out 42.73M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,220,900
Open 25.53
Previous Close 25.52
Day's Range 24.21 - 25.75
52-Week Range 4.44 - 30.96
Beta 1.68
Analysts Buy
Price Target 19.00 (-23.01%)
Earnings Date May 3, 2024

About IMNM

Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2020
Employees 37
Stock Exchange NASDAQ
Ticker Symbol IMNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for IMNM stock is "Buy" and the 12-month stock price forecast is $19.0.

Price Target
$19.0
(-23.01% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...

1 hour ago - Business Wire

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful...

2 days ago - Business Wire

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

EDINBURGH, Scotland--(BUSINESS WIRE)--Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASD...

10 days ago - Business Wire

Immunome to Participate in the Leerink Partners Global Biopharma Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...

21 days ago - Business Wire

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...

27 days ago - Business Wire

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announc...

Other symbols: ADXS
5 weeks ago - Business Wire

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...

5 weeks ago - Business Wire

Immunome Announces Pricing of Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...

6 weeks ago - Business Wire

Immunome Announces Proposed Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...

6 weeks ago - Business Wire

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

BOTHELL, Wash. & MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to...

Other symbols: ADXS
7 weeks ago - Business Wire

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o...

7 weeks ago - Business Wire

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

BOTHELL, Wash. & SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worl...

Other symbols: ZNTL
2 months ago - Business Wire

Immunome Appoints Phil Roberts as Chief Technical Officer

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...

3 months ago - Business Wire

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...

3 months ago - Business Wire

Immunome Appoints Carol A. Schafer to Board of Directors

BOTHELL, Wash. & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...

3 months ago - Business Wire

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it ...

Other symbols: BCEL
3 months ago - Business Wire

Immunome to Present at the Stifel 2023 Healthcare Conference

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Cla...

4 months ago - Business Wire

Immunome Reports Third Quarter 2023 Financial Results

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financi...

5 months ago - Business Wire

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appo...

5 months ago - Business Wire

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appo...

5 months ago - Business Wire

Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it ...

6 months ago - Business Wire

Immunome Reports Second Quarter 2023 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to i...

8 months ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether Immunome, Inc. has obtained a Fair Price in its Private Placement and its transaction with Morphimmune

MILWAUKEE , June 30, 2023 /PRNewswire/ -- Ademi LLP is investigating Immunome (Nasdaq: IMNM) for possible breaches of fiduciary duty and other violations of law in its private placement and its transa...

9 months ago - PRNewsWire

IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the all-stock merger of Morphimmune and Immunome, Inc. (NASDAQ: IMNM) is fair to Immunome shareholder...

9 months ago - Business Wire

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

EXTON, Pa. & SEATTLE--(BUSINESS WIRE)--Immunome (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B-cell platform to discover and develop antibody therapeutics to improv...

9 months ago - Business Wire